USA 118:e2025347118
2025 marked major milestones in CNS drug development, with multi-billion-dollar partnerships including AbbVie/Gilgamesh, Novartis/Avidity and Roche/Manifold highlighting robust investment across numerous therapeutic areas
In this article, we will delve into the science behind GLP-1, explore its role in weight management, and understand how it could be a game-changer in the quest for a healthier weight
2015;7:a006080 Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al
PubMed Systematic reviewGLP-1 class evidence2025 Discontinuing glucagon-like peptide-1 receptor agonists and body habitus Used for pages discussing stopping therapy, weight regain, and long-term planning